Mesoblast Limited (NASDAQ:MESO) has been assigned a $14.00 target price by equities research analysts at Maxim Group in a research note issued on Wednesday. The firm presently has a “buy” rating on the stock. Maxim Group’s price objective would suggest a potential upside of 159.26% from the company’s previous close.
A number of other brokerages have also recently issued reports on MESO. Credit Suisse Group set a $11.00 target price on shares of Mesoblast Limited and gave the company a “hold” rating in a research report on Tuesday, July 18th. BidaskClub cut shares of Mesoblast Limited from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Cantor Fitzgerald set a $20.00 target price on shares of Mesoblast Limited and gave the company a “buy” rating in a research report on Wednesday, August 16th. CIBC started coverage on Mesoblast Limited in a research note on Thursday, August 31st. They issued an “outperform” rating and a $16.00 price target for the company. Finally, Oppenheimer Holdings, Inc. started coverage on Mesoblast Limited in a research note on Thursday, August 31st. They issued an “outperform” rating and a $16.00 price target for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $13.14.
Shares of Mesoblast Limited (MESO) opened at $5.40 on Wednesday. Mesoblast Limited has a 52-week low of $4.39 and a 52-week high of $12.50.
WARNING: This report was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/11/15/maxim-group-analysts-give-mesoblast-limited-meso-a-14-00-price-target.html.
About Mesoblast Limited
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.